Bolt Biotherapeutics Shares Rise 12% After CFO Buys 5,000 Shares [MarketWatch]
Bolt Biotherapeutics, Inc. (BOLT)
Company Research
Source: MarketWatch
In a filing to the Securities and Exchange Commission on Thursday, the company said Finance Chief William Quinn bought 5,000 shares from Dec. 6 through Dec. 8 at an average price of $4.68. Mr. Quinn now has direct ownership of about 20,000 Bolt shares. The stock hit its 52-week low of $4.27 on Thursday after trading as high as $10.50 last Friday. On Monday, Bolt Biotherapeutics said it saw positive interim clinical data from its ongoing Phase 1/2 study of BDC-1001, an immune-stimulating antibody conjugate. The biotechnology company said BDC-1001 demonstrated a favorable safety and tolerability profile at all evaluated doses and schedules, showing early signs of clinical activity with corresponding biomarker changes in the tumor microenvironment of post-treatment tumor biopsies. The company said the favorable safety profile of BDC-1001 allows for continued enrollment in the dose escalation portion of the study, and the company's refined PK model based on data from more than
Show less
Read more
Impact Snapshot
Event Time:
BOLT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BOLT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BOLT alerts
High impacting Bolt Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
BOLT
News
- Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.MarketBeat
- Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateGlobeNewswire
- Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare ConferenceGlobeNewswire
BOLT
Earnings
- 11/9/23 - Beat
BOLT
Analyst Actions
- 3/22/24 - HC Wainwright
BOLT
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- BOLT's page on the SEC website